Enhance your practice with CME and tools that focus on the management of neurological conditions.
FA hiPSCs in Translational Drug Development
Omaveloxolone in Friedreich’s Ataxia: Early Real-World Signals
Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
Aaron Miller, MD
Addressing Social and Systemic Barriers in Schizophrenia
Shelina Ramnarine, PhD
Margaret Emerson, DNP, APRN, PMHNP-BC
Challenging the Status Quo in Schizophrenia Treatment
Stephen Marder, MD
Advancing Pediatric MS Care: Insights from AAN 2026
Elizabeth Wilson, MD
Updates in MS Care: Key Topics at AAN 2026
The Social Brain in Schizophrenia
Michael Green, PhD
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
Orlando, Florida
Target Locked in gMG: Why T2T Matters
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Turning Flares Into Function: Flag Uncontrolled Disease
Minimal By Design: Define MSE Endpoints
Nutrition and the Gut-Brain Connection in Schizophrenia
Deanna L. Kelly, PharmD, BCPP
Depression as a Signal of MS Progression
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Family Planning in Patients with Multiple Sclerosis
11:45 AM - 12:45 PM ET
Proactive Pregnancy Planning and Reproductive Care in MS
Riley Bove, MD, MMSc
FcRn: Same Class, Different Paths—Spot Agent Differentiators
The 2-Point Signal: Apply ≥2-Point Rule
Loading...
We're glad to see you're enjoying Global Neurology Academy… but how about a more personalized experience?
Press cancel to remain on Global Neurology Academy. Press the link below or the continue button to keep going.